Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Up 6.46%
As of Tuesday, November 03, Kailera Therapeutics, Inc.’s KLRA share price has surged by 6.46%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Commentary & Analysis
Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Down 6.07%
As of Monday, November 02, Kailera Therapeutics, Inc.’s KLRA share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Down 5.20%
As of Friday, October 23, Kailera Therapeutics, Inc.’s KLRA share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Michael Rose
Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Up 7.44%
As of Tuesday, October 20, Kailera Therapeutics, Inc.’s KLRA share price has surged by 7.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Up 12.95%
As of Tuesday, October 20, Kailera Therapeutics, Inc.’s KLRA share price has surged by 12.95%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | KLRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,632.2 | $219.1 | 52% |
|
| Shares Out (Mil) | 102.2 | 53.4 | 62% |
|
| Institutional Ownership | 99.9% | 92.9% | 96% |
|
| Float (Mil) | 58.5 | 41.4 | 50% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 958 | 455 | 69% |
|
| Price Change (52-week) |
na | 46.6% | na |
|
| Growth | KLRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($1.010) | ($4.097) | ($4.296) | |
| Month Ago EPS | ($1.010) | ($4.097) | ($4.296) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.925) | ($3.971) | ($4.097) | |
| Year/Year Chg | (7.3%) | na | na | |
| Financials | KLRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($292) | ($44) | 5% |
|
| EPS (TTM) | ($2.254) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($222) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $1,168 | $174 | 43% |
|
| Valuation | KLRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.46 | 2.11 | 41% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | KLRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (48.2%) | (47.0%) | 12% |
|
| ROE | (52.2%) | (52.2%) | 15% |
|
| Liabilities to Assets | 7.7% | 29.6% | 4% |
|
| F-Score | 1 | 2 | na |
|
Kailera Therapeutics, Inc. did not pass any screens on 11/3/2026.
